Our vision is to defeat cancer and advance health equity for ALL communities through patient-centric social innovation and intentional, mission-aligned impact investing.

BrightEdge exists to accelerate the American Cancer Society's goal to reduce cancer mortality, end pain and suffering, and advance health equity

Investing for science, social impact, and sustainability

BrightEdge invests invests in entrepreneurial early-stage companies developing cutting-edge cancer-focused therapeutics, diagnostics, devices, and technologies to bring innovative solutions to market.

Fighting for a World Without Cancer

BrightEdge is led by a world-class team of investors, operators, and entrepreneurs to accelerate the commercialization of the breadth of solutions needed to target cancer from all perspectives.

News

American Cancer Society’s VC arm partners with Third Rock on oncology companies

Cancer startups aren’t exactly underfunded — as a disease area, oncology has commanded investors’ attention for the last decade. But the American Cancer Society sees gaps.

Third Rock Ventures Teams Up With American Cancer Society’s Venture Fund

The biotech venture firm will bring the society’s BrightEdge venture arm into cancer startup deals

BrightEdge Annual Report 2021

In 2021, BrightEdge reemerged during the darkness of the COVID-19 pandemic with resolve and focus to pave new paths for the American Cancer Society (ACS), for healthcare innovation, and for people with cancer and their caregivers.